Glioblastoma Multiforme Clinical Trial
Official title:
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Background:
- Growth of new blood vessels (angiogenesis) provides many tumors, including brain
tumors, with needed nutrients and oxygen for cancer cells to survive. One possible
treatment for different kinds of cancer involves treatment with drugs that slow or stop
angiogenesis and prevent further tumor growth.
- Vandetanib is an oral medication known to block angiogenesis and has shown significant
antitumor activity in laboratory and animal studies. Vandetanib appears to be well
tolerated by patients at specific daily doses.
- Carboplatin is a drug that interrupts division of cancer cells and has been shown to be
a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating
brain tumors, but researchers are interested in gathering more information about how it
works as a treatment for patients who have not responded to initial surgery, radiation,
or chemotherapy.
Objective:
- To determine the safety and effectiveness of vandetanib and carboplatin, given together or
sequentially, against recurrent high-grade gliomas.
Eligibility:
- Adults diagnosed with a malignant glioma who have received standard treatments that no
longer appear to be effective.
Design:
- Patients will be assigned to one of two groups. Group 1 patients (combination group)
will receive oral vandetanib for 28 days and intravenous (IV) carboplatin (once at the
beginning of the 28-day cycle). Group 2 patients (sequential group) will receive IV
carboplatin alone (once at the beginning of the 28-day cycle) and then oral vandetanib
(300 mg daily) for 28 days if the tumor grows or the patient develops unacceptable
carboplatin toxicity.
- Treatment will continue in 28-day cycles for 1 year for both groups.
- Patients will undergo a number of tests and procedures during the treatment cycle,
including physical examinations, routine laboratory tests, electrocardiograms, and
magnetic resonance imaging (MRI) scans
- At the end of 1 year of treatment, patients will be reevaluated for possible
continuation of drug therapy.
Background:
In vivo experiments have documented the ability of vandetanib (ZD6474) to inhibit tumor
growth in various preclinical tumor models. Given the pronounced neovasculature associated
with malignant gliomas, and abundant published data demonstrating the dependence of glioma
growth on the maintenance and proliferation of this neovasculature, vandetanib represents a
potentially promising new therapeutic approach to these otherwise refractory tumors. Phase
II data of vandetanib for recurrent glioblastomas conducted at the National Institutes of
Health showed promising activity but responses were usually short-lasting.
Carboplatin has shown activity as monotherapy in the treatment of recurrent malignant
gliomas in adults and preclinical data generated at Dr. Fine s laboratory demonstrate
additive anti-glioma activity with vandetanib. The safety profile of carboplatin and the
preclinical and clinical data supports its use in combination with vandetanib in patients
with malignant gliomas.
Vandetanib is also an EGFR inhibitor and it has been demonstrated that the presence of the
EGFRvIII mutant and/or the presence of an intact PTEN and non-phosphorylated AKT predict for
a higher likelihood of response to the EGFR inhibitors Tarceva and Iressa.
Objectives:
To establish data regarding the anti-tumor activity of vandetanib in combination with
carboplatin and single agent carboplatin and to collect information regarding the spectrum
of toxicities.
To determine if the presence of the EGFRvIII mutant and/or the presence of an intact PTEN
and non-phosphorylated AKT predict for a higher likelihood of response to vandetanib.
Eligibility:
Patients with histologically proven malignant glioma are eligible for this study.
Design:
Patients will be randomized (1:1) to one of two groups. Patients in group one will be
treated with vandetanib (300 mg daily for patients not on enzyme inducing anti-epileptic
drugs (EIAEDs) and 400 mg daily for patients on EIAEDs) and with carboplatin (area under the
concentration-time curve at steady-state [AUC], 6mg/mL x min) once every 4-week cycle (
combination group ). Patients in group two will receive carboplatin alone (AUC 6mg/mL x min)
once every 4-week cycle. Patients who develop tumor progression or unacceptable toxicity on
carboplatin alone (group 2) can then receive single agent vandetanib (300 mg daily for
patients not on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg daily for patients
on EIAEDs) in 4-week cycles ( sequential group ). A total of 128 evaluable patients will be
analyzed. The total accrual ceiling will allow for 74 patients to be enrolled in the GBM
stratum and 74 patients in the AG stratum (total 148) to factor in replacing those patients
who come off treatment prior to cycle 1.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05023551 -
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
|
Early Phase 1 | |
Recruiting |
NCT06059690 -
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116411 -
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
|
Phase 2 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00038493 -
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Recruiting |
NCT01923922 -
CT Perfusion in the Prognostication of Cerebral High Grade Glioma
|
N/A | |
Completed |
NCT01956734 -
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
|
Phase 1 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Completed |
NCT01301430 -
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
|
Phase 1/Phase 2 | |
Completed |
NCT01402063 -
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
|
Phase 2 | |
Terminated |
NCT00990496 -
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Recruiting |
NCT05366179 -
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
|
Phase 1 | |
Recruiting |
NCT04277221 -
ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
|
Phase 3 |